Prelude Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-31,694
| Closed | -$683K | – | 1217 |
|
|
2025
Q4 | $683K | Buy |
31,694
+20,530
| +184% | +$399K | 0.05% | 423 |
|
|
2025
Q3 | $170K | Sell |
11,164
-19,167
| -63% | -$249K | 0.01% | 983 |
|
|
2025
Q2 | $268K | Buy |
30,331
+7,253
| +31% | +$63.7K | 0.03% | 659 |
|
|
2025
Q1 | $181K | Buy |
23,078
+140
| +0.6% | +$1.17K | 0.01% | 966 |
|
|
2024
Q4 | $241K | Buy |
22,938
+11,215
| +96% | +$136K | 0.02% | 900 |
|
|
2024
Q3 | $154K | Sell |
11,723
-60,271
| -84% | -$918K | 0.01% | 1102 |
|
|
2024
Q2 | $1.01M | Buy |
+71,994
| New | +$1.17M | 0.07% | 317 |
|
|
2024
Q1 | – | Sell |
-12,076
| Closed | -$171K | – | 1315 |
|
|
2023
Q4 | $171K | Buy |
+12,076
| New | +$142K | 0.01% | 978 |
|
|
2021
Q1 | – | Sell |
-51,118
| Closed | -$341K | – | 1523 |
|
|
2020
Q4 | $341K | Buy |
+51,118
| New | +$320K | 0.01% | 860 |
|
|
2020
Q3 | – | Sell |
-20,815
| Closed | -$168K | – | 1810 |
|
|
2020
Q2 | $168K | Buy |
+20,815
| New | +$184K | 0.01% | 788 |
|
|
2017
Q4 | – | Sell |
-6,900
| Closed | -$72K | – | 1358 |
|
|
2017
Q3 | $72K | Buy |
6,900
+2,900
| +73% | +$27.7K | 0.01% | 990 |
|
|
2017
Q2 | $44K | Buy |
4,000
+1,400
| +54% | +$14.1K | ﹤0.01% | 1040 |
|
|
2017
Q1 | $25K | Buy |
2,600
+2,500
| +2,500% | +$25K | ﹤0.01% | 1237 |
|
|
2016
Q4 | $1K | Sell |
100
-24,686
| -100% | -$271K | ﹤0.01% | 1495 |
|
|
2016
Q3 | $307K | Buy |
+24,786
| New | +$324K | 0.03% | 425 |
|
|
2014
Q2 | – | Sell |
-11,210
| Closed | -$150K | – | 1902 |
|
|
2014
Q1 | $150K | Buy |
+11,210
| New | +$120K | 0.02% | 839 |
|
Other funds holding AVDL
Prelude Capital Management's AVDL Position: Q1 2026 in Review
Prelude Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 31,694 shares — an estimated $683K sold.
Prelude Capital Management first reported a position in AVDL in Q1 2014 and held it in 16 quarters. The position peaked at $1.01M in Q2 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Prelude Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Prelude Capital Management sold 31,694 Avadel Pharmaceuticals shares in Q1 2026, an estimated $683K.
- Prelude Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 16 quarters.
- Prelude Capital Management's Avadel Pharmaceuticals position peaked at $1.01M in Q2 2024.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.